Biotech Values

[mcbio]

POZN @ Roth (3/14/12)

1. POZN expects PA32540 to be priced at $1/day, thus lessening any incentive to try and buy the individual drug components separately. POZN also expects their drug to have advantages over the individual components taken separately.

2. POZN expects a partner for PA32540 towards 4Q12 and potential product launch at end of 2013/early 2014.

3. POZN expects peak sales potential for PA32540 of about $400M (certainly doesn't seem like an aggressive estimate to me) with 90% gross margin. Hopefully they land lucrative terms in any potential partnership and not just a low double-digit royalty rate. They want a partner worldwide.